Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inhibikase TherapeuticsIKT 34 14-Day RSI is 64.54 as of Jul. 23, 2026. GuruFocus rates IKT with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,424 Biotechnology companies, Inhibikase Therapeutics ranks worse than 95.22% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Inhibikase Therapeutics 14-Day RSI Related Terms
IKT vs FHTX, OBIO, FULC: 14-Day RSI Comparison
For the Biotechnology subindustry, Inhibikase Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibikase Therapeutics 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Inhibikase Therapeutics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics (IKT) has a 14-Day RSI of 64.54 as of Jul. 23, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Inhibikase Therapeutics and its competitors. According to the industry distribution chart, Inhibikase Therapeutics ranks #1356 out of 1424 companies in the Biotechnology industry, placing it in the top 95.2%.
Is Inhibikase Therapeutics' 14-Day RSI too high?
Inhibikase Therapeutics' current 14-Day RSI is 64.54. The Biotechnology industry median 14-Day RSI is 45.23. Inhibikase Therapeutics' value of 64.54 is 42.7% above this industry median. Based on the distribution chart, Inhibikase Therapeutics ranks #1356 out of 1424 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Inhibikase Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' 14-Day RSI compare to FHTX and OBIO?
According to the Biotechnology industry distribution chart, Inhibikase Therapeutics ranks #1356 out of 1424 companies for 14-Day RSI. This places Inhibikase Therapeutics in the lower half of its industry. The industry median 14-Day RSI is 45.23. Inhibikase Therapeutics' value of 64.54 is 42.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 45.23, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inhibikase Therapeutics's current 14-Day RSI of 64.54 is 42.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Inhibikase Therapeutics and its competitors. For the Biotechnology industry, the median 14-Day RSI is 45.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhibikase Therapeutics's current 14-Day RSI is 64.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current 14-Day RSI of 64.54. The current 14-Day RSI is 64.54 and 42.7% above the Biotechnology industry median of 45.23. Inhibikase Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current 14-Day RSI is 64.54 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
34GF Score
Get the complete analysis for IKT
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IKT has been successfully added to your 
